Posted by Michael Wonder on 01 Aug 2024
Immuneering granted FDA fast track designation for IMM-1-104 in first-line pancreatic cancer
31 July 2024 - IMM-1-104 fast track designation now granted for the treatment of both first and second-line pancreatic ductal adenocarcinoma.
Immuneering today announced that the US FDA granted fast track designation for its lead clinical-stage program, IMM-1-104, as a first-line treatment for patients with pancreatic ductal adenocarcinoma.
